Related Experiment Videos
Prolonged survival after intraperitoneal interleukin-2 immunotherapy for recurrent ovarian cancer
David R Minor1, Samantha P Moores2, John K Chan3
1California Pacific Medical Center Research Institute, 2200 Webster St. Suite 511, San Francisco, CA 94115, United States.
Gynecologic Oncology Reports
|October 17, 2017
Abstract:
•A case report of a 14 year remission of recurrent ovarian cancer with intraperitoneal aldesleukin (IL-2) is presented.•Intraperitoneal IL-2 was given with little toxicity.•Immunotherapy may have the potential for durable remissions in ovarian cancer.